Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other firms that posted double-digit gains on Thursday. Wall Street’s main indices ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%, and achieved a full year of operating and net income profitability. Despite strong fundamentals, HIMS stock price has ...

Listen to more stories on the Noa app. The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales ...

Hims & Hers Health, Inc. (HIMS) shares rallied 27.7% in the last trading session to close at $59.18. This move can be attributable to notable volume with a higher number of shares being traded ...

The GLP-1 wars are heating up. After telehealth brand Hims & Hers aired its first Super Bowl commercial Sunday night, competitor Novo Nordisk, which makes competing weight loss drugs Ozempic and ...

“To us, it's clear that it's not about the ad — it's about the message.” In the week leading up to the Super Bowl, health care groups and lawmakers alleged that Hims & Hers didn't abide by advertising ...

Hims & Hers is a multispecialty telehealth platform that connects consumers to medical care for numerous conditions related to mental health, sexual health, dermatology and primary care.